Memorandum
The FDA has approved Genentech's Lucentis to treat diabetic retinopathy in patients with diabetic macular edema. This new indication for Lucentis was granted breakthrough therapy designation and received a priority review. We know from data that 33% of adults with diabetes 40 years or older had some form of diabetic retinopathy. What a major win for patients and we thank Genentech for working to expand Lucentis' indication for such an unmet need.